Featured News See All October 21, 2024 REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 September 17, 2024 REGENXBIO Appoints Mitchell Chan as Chief Financial Officer September 3, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect Year All202420232022202120202019201820172016201520142013201220112009 Oct 21, 2024 REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 Oct 18, 2024 REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting Sep 23, 2024 REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference Sep 17, 2024 REGENXBIO Appoints Mitchell Chan as Chief Financial Officer Sep 03, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect Aug 29, 2024 REGENXBIO to Participate in Upcoming Investor Conferences Aug 27, 2024 REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
Oct 21, 2024 REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Oct 18, 2024 REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Sep 03, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
Aug 27, 2024 REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium